Keros Therapeutics’ (KROS) “Buy” Rating Reiterated at Guggenheim

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “buy” rating reaffirmed by investment analysts at Guggenheim in a report issued on Wednesday,Benzinga reports. They presently have a $102.00 price target on the stock, up from their previous price target of $96.00. Guggenheim’s price target suggests a potential upside of 57.87% from the company’s current price.

Several other research firms have also weighed in on KROS. Bank of America dropped their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Jefferies Financial Group assumed coverage on Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating on the stock. Wedbush restated an “outperform” rating and set a $84.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Finally, Scotiabank started coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price for the company. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $89.56.

Keros Therapeutics Price Performance

Shares of KROS opened at $64.61 on Wednesday. The company has a 50-day moving average of $60.05 and a two-hundred day moving average of $52.56. The stock has a market cap of $2.62 billion, a price-to-earnings ratio of -12.40 and a beta of 1.20. Keros Therapeutics has a one year low of $27.31 and a one year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million during the quarter. During the same period last year, the company earned ($1.33) earnings per share. The business’s revenue for the quarter was up 4750.0% on a year-over-year basis. Analysts anticipate that Keros Therapeutics will post -5.28 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its position in Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after purchasing an additional 46,041 shares during the last quarter. Barclays PLC increased its stake in shares of Keros Therapeutics by 140.1% in the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after buying an additional 35,022 shares in the last quarter. Wellington Management Group LLP acquired a new stake in shares of Keros Therapeutics in the third quarter valued at $868,000. Point72 DIFC Ltd raised its holdings in shares of Keros Therapeutics by 9.8% in the third quarter. Point72 DIFC Ltd now owns 19,255 shares of the company’s stock valued at $1,118,000 after buying an additional 1,715 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its position in Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after buying an additional 577,220 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.